Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 4Triple Negative Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Pathologic Complete Response 1Neutropenia 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Limited Stage Small Cell Lung Cancer 1Hemangiosarcoma 1Carcinoma, Transitional Cell 1

Interventions

trifluridine tipiracil drug combination 2pegylated granulocyte colony-stimulating factor 2trilaciclib 1plerixafor 1eravacycline 1Vancomycin 1Teicoplanin 1PM 01183 1Ofloxacin 1Metronidazole 1Meropenem 1Loratadine 1Levofloxacin 1Ciprofloxacin 1Ceftazidime 1Cefepime 1Bevacizumab 1Amikacin 1Algorithms 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neutropenia × trilaciclib × 1 year × Clear all
NCT05578326 2026-03-30

Study of Trilaciclib and Lurbinectidin

UNC Lineberger Comprehensive Cancer Center

Phase 2 Recruiting
30 enrolled
Thoracic

Lung Neoplasms, Neutropenia, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡